New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:25 EDTACAD, ACAD, ACAD, JAZZ, JAZZ, JAZZ, FRX, FRX, FRX, MDCO, MDCO, MDCO, SLXP, SLXP, SLXP, VRX, VRX, VRX, VRTX, VRTX, VRTX, SGMO, SGMO, SGMO, PCYC, PCYC, PCYC, PDLI, PDLI, PDLI, ISIS, ISIS, ISIS, HZNP, HZNP, HZNP, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, BDSI, BDSI, BDSI, NKTR, NKTR, NKTRPiper Jaffray's technical analyst holds an analyst/industry conference call
Senior Technical Analyst Johnson provides an overview of the firm's covered universes, Biotech & Specialty Pharmaceuticals, from the viewpoint of a technical analyst on an Analyst/Industry conference call to be held on January 21 at 10 am.
News For ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR From The Last 14 Days
Check below for free stories on ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
September 5, 2014
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information
10:36 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
10:18 EDTGILDGilead shares defended at Bernstein
Subscribe for More Information
10:11 EDTGILDGilead slips after VP discusses low-cost Sovaldi for 80 countries
Subscribe for More Information
10:05 EDTPCYC, VRX, CELGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
10:05 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:51 EDTGILDGilead drops, trades in wide range
Subscribe for More Information
09:50 EDTGILDGilead down 3.5% after reports of potential generic Sovaldi deal coming
09:49 EDTGILDGilead near deal for generic Sovaldi for developing countries, Bloomberg reports
Subscribe for More Information
09:43 EDTGILDGilead drops 6%, or $6.41, to $100.45
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA YHOO WFM SLW ABX GOOG FB BIDU
05:41 EDTVRTXVertex upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded Vertex Pharmaceuticals to Buy saying it sees a 90% probability of approval for the company's VX-809/Kalydeco combo for cystic fibrosis and a higher likelihood of M&A following the positive Phase 3 data in June. Goldman raised its price target for shares to $131 from $109.
September 4, 2014
17:57 EDTPCYCPharmacyclics initiated with a Neutral at SunTrust
Target $140.
17:56 EDTCELGCelgene initiated with a Buy at SunTrust
Target $121.
17:16 EDTVRXValeant initiated with a Buy at ISI Group
Target $159.
11:30 EDTGILDStocks with call strike movement; AAL GILD
American Airlines (AAL) November 44 call option implied volatility increased 6% to 39, Gilead (GILD) November 130 call option implied volatility decreased 5% to 40 according to IVolatility.
09:44 EDTVRXValeant, Ackman deliver another 2.8% consent vote to Allergan, CNBC reports
Valeant (VRX) and Bill Ackman delivered another 2.8% consent vote to Allergan, bringing its total vote to call a special meeting to 33.8%, CNBC's David Faber reports, citing sources. A special meeting has been set for December 18, Faber added.
09:35 EDTGILDActive equity options trading on open
Subscribe for More Information
07:33 EDTCELGCelgene announces REVLIMID Phase III FIRST trial met primary endpoint
Subscribe for More Information
07:21 EDTGILDMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use